Salvia BioElectronics implants first patient in pivotal U.S. migraine study

Salvia BioElectronics has reached an important milestone with the first patient implanted with its investigational MySalvia System in RECLAIM-II, a pivotal U.S. clinical study in adults with resistant migraine.

The study will evaluate the safety and effectiveness of Salvia’s ultra-thin, implantable neuromodulation system, designed to help prevent migraine attacks. Approximately 150 patients are expected to participate across more than 20 clinical sites in the United States.